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The association between treatment variation and survival of women with endometrial cancer was investigated. A retrospective
cohort based upon the complete Scottish population registered on in-patient and day-case hospital discharge data (Scottish
Morbidity Record-1) and cancer registration (Scottish Morbidity Record-6) coded C54 and C55 in ICD10, between 1st
January 1996 to 31st December 1997 were analysed. Seven hundred and three patients who underwent surgical treatment
out of 781 patients that were diagnosed with endometrial cancer in Scotland during 1996 and 1997. The overall quality of
surgical staging was poor. The quality of staging was related to both the year that the surgeon passed the Member of the
Royal College of Obstetricians and Gynaecologists examination and also to ‘specialist’ status but was not related to surgeon
caseload. Two clinically important prognostic factors were found to be associated with survival; whether the International
Federation of Obstetrics and Gynaecology stage was documented, RHR=2.0 (95% CI=1.3 to 3.1) and also to the use of
adjuvant radiotherapy, RHR=2.2 (95% CI=1.5 to 3.5). The associations with survival were strongest in patients with advanced
disease, International Federation of Obstetrics and Gynaecology stages 1C through to stage 3. Deﬁciencies in staging and
variations in the use of adjuvant radiotherapy represent a possible source of avoidable mortality in patients with endometrial
cancer. Consequently, there should be a greater emphasis on improving the overall quality of surgical staging in endometrial
cancer.
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Endometrial cancer is the second most common gynaecological
cancer in the UK (Coleman et al, 1999) with approximately 400
cases diagnosed annually in Scotland. International comparisons
show that survival in the UK, and in particular Scotland, is poor
compared to other European countries (Gatta et al, 1998) but this
data, from cancer registries, does not reveal the reasons for poor
survival. There is little published in the literature describing varia-
tions in the management of this disease. An audit in south-east
England found that inappropriate management was related to
poorer survival outcome (Tilling et al, 1998). Endometrial cancer,
unlike other gynaecological cancers, has traditionally been regarded
as easy to treat (Lawton, 1997) nevertheless 25% of women will die
of recurrence within 5 years of diagnosis (ISD, 2000).
The overall aim of this study was to improve the understanding
of variations in survival of women with endometrial cancer in
Scotland. Speciﬁcally the objectives of the Scottish endometrial
cancer study were to describe current practice, to investigate the
consistency of staging and to relate these to survival outcomes.
Some of this other information will be reported elsewhere. This
study describes the relationship between variations in the adequacy
of surgical staging and the use of adjuvant radiotherapy with
patient survival. This is an important issue as a greater emphasis
in the quality of staging represents a ‘correctable’ aspect of clinical
management that may lead to improved patient survival. This is
particularly relevant, as national cancer plans drawn up for
England (Department of Health, 1999, 2000), and in preparation
for Scotland have been stimulated in part by the unfavourable
comparisons between the UK and Europe.
METHODS
The study was a retrospective case note review of all women with
endometrial carcinoma who were resident in Scotland with a diag-
nosis ﬁrst made between 1 January 1996 and 31 December 1997,
the latest years for which complete data are currently available.
Cases of endometrial carcinoma were identiﬁed from the Scottish
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discharge data). Cases were deﬁned as patients who were coded
as C54 and C55 in the 10th revision of the International Classiﬁca-
tion of Disease (ICD10). Prior to March 1996, the equivalent codes
in ICD9 were used. At the end of the study, Cancer Registration
(SMR-6) and SMR-1 data sets were linked to ensure completeness
and any additional records were reviewed.
Prior to this study, a pilot study examining case records was
conducted at a teaching hospital and at a district general hospital.
This allowed the generation of hypotheses and informed the choice
of variables to be collected. Data was collected from hospital medi-
cal records on diagnosis and staging, surgical treatment and
adjuvant radiotherapy. Two experienced clinical data abstractors
recorded data according to deﬁnitions pre-deﬁned by the study
committee. The study was conducted under the auspices of the
Scottish Programme for Clinical effectiveness in Reproductive
Health (SPCERH) and permissions were sought from MREC, the
privacy committee of the Information and Statistics Division,
hospital trusts and all consultant gynaecologists in Scotland. Data
was collected from both the hospital of the deﬁnitive operation
and radiotherapy centres. Pathology reports were reviewed by
one of the investigators with experience in gynaecological oncology
(SCC) who assigned a ‘retrospectively derived’ FIGO (International
Federation of Obstetrics and Gynaecology) stage to every case. This
was based upon the best available information from the clinical
and pathology reports using the published FIGO staging nomencla-
ture (Shepherd, 1989). If the cytology result was unavailable the
result was assumed to be negative for the purpose of allocating a
FIGO stage. Cases were deﬁned as ‘unstageable’ if there was no
operation, there was insufﬁcient histological information or if there
were synchronous tumours present. The data abstractors cross-
checked 1 in 50 (24) abstracted records for accuracy. Data was
entered into an Access-97 database (Microsoft Inc., 1997) and
statistical analysis was carried out in SPSSv9.0 for Windows (SPSS
Inc., 2000).
Patients were grouped into four categories on the basis of their
retrospective FIGO stage. These groups represented the likelihood
of metastatic spread and thus the use of adjuvant radiotherapy:
‘low risk’ of metastatic spread (FIGO stages 1AG1 and 1BG1),
‘intermediate risk’ (FIGO stages 1AG2/G3, 1BG2/G3, 1CG1/G2),
‘high risk’ (FIGO stages 1CG3 and stages 2/3/4) and ‘unstageable’.
The ‘intermediate’ risk group represents the study group of a
recent randomised trial of post-operative radiotherapy in endome-
trial cancer (Creutzberg et al, 2000).
Survival data were obtained by computerised probability match-
ing to the Registrar General’s death records (Kendrick and Clarke,
1993). The date of censoring was 31st March 2000. We found 59
cases of proven endometrial cancer that were not linkable to the
Registrar General’s death records. These cases were included in
the analysis. In these cases the date of censoring was deﬁned as
the date of data abstraction from the case record if there was no
indication of death. The rationale for this was that case records
are usually ‘marked’ by medical record’ staff when a patient
becomes deceased. The Carstairs classiﬁcation of socio-economic
deprivation (Carstairs and Morris, 1991) was used to allocate
patients to categories of socio-economic deprivation. The seven
categories were aggregated to three categories (1 and 2, 3–5, 7
and 8) to facilitate analysis.
The results of the initial pilot audit indicated that staging was
poorly performed. Two aspects of staging were examined, whether
ﬂuid was sent for cytological examination and whether the FIGO
stage was calculated and documented in the medical record by
either the surgeon or the pathologist. We used multiple logistic
regression to explore four factors that were initially perceived to
have a potential bearing on the quality of surgical staging. These
were ‘specialist’-gynaecological surgeons; surgeon caseload, the date
of postgraduate education (MRCOG pass date) and hospital
volumes. For the purposes of this study a gynaecology cancer
‘specialist’ was deﬁned as a gynaecologist performing radical
surgery for cervical carcinoma in 1996/7. Prior to the study, it
had been noted that some senior clinicians were less likely to
perform staging as thoroughly as younger consultants. Until
1988, the staging of endometrial cancer was based on the results
of a clinical examination under anaesthesia. The International
Federation of Obstetrics and Gynaecology (FIGO) introduced a
system in 1988 that involved combining information collected at
the time of surgery with histological data from the subsequent
pathology report. This change was ﬁrst reported in the UK litera-
ture in 1989 (Shepherd, 1989). Each gynaecologist was categorised
according to their year of passing the examination of Member of
the Royal College of Obstetricians and Gynaecologists (MRCOG)
(RCOG, 1997). In each case the senior surgeon present at opera-
tion was classiﬁed as obtaining MRCOG before or after 1989.
This allowed gynaecologists to be categorised according to the
FIGO staging system that they had been accustomed to during
their early training. Surgeon caseload was represented by the
number of cases of endometrial cancer that had been treated over
the 2 years of the study cohort. Likewise the hospital volume repre-
sents the number of cases of endometrial cancer that were treated
in 1996/7.
A number of possible factors that might be related to survival
were explored.
Univariate analysis was used to relate each possible prognos-
tic factor with survival using the Kaplan–Meier method. The
Log rank statistic was used to compare individual survival
curves. The primary end point in the survival analysis was
death from any cause. This was used instead of the cancer
speciﬁc cause of death due to acknowledged inaccuracies in
death certiﬁcate information (Maudsley and Williams, 1993).
In the ﬁnal analysis a Cox proportional hazards model was
used (Katz, 1999).
RESULTS
One thousand and eighty ﬁve possible cases were identiﬁed from
SMR-1 and a further 149 cases from SMR-6. Of these, 67 records
could not be located and 299 cases were excluded of these 172
cases were diagnosed out with 1996/7 and 127 cases were tumours
other than uterine cancer. A further 87 cases of uterine sarcoma
were also excluded. Thus, 781 patients with endometrial carcinoma
diagnosed in 1996/7 were available for analysis. Of these, 703 were
initially treated by surgery and this is the group discussed in this
study.
The FIGO stage was deﬁned in the case record by the surgeon
and/or pathologist in only 36.4% of cases despite the fact that
extent of invasion and tumour grade was present in 88.6% of case
records. Fluid was sent for cytological examination in only 46.6%
of cases. The intra-peritoneal cytology rate can be validated. A
98% concurrence was found between the operation record and
whether a cytology report was issued. This suggests that if this
aspect of staging was performed then it was recorded in the opera-
tion record.
Table 1 shows the surgeon and workload factors that were asso-
ciated with more comprehensive staging. Table 2 shows the results
of the multiple logistic regression analysis that was used to identify
the strengths of association between the factors. In each of the
analyses there is an increased likelihood of more adequate staging
by surgeons passing the MRCOG after 1989 or having ‘specialist’
status. No independent association was observed between surgeon
caseload and staging quality despite the observation that ‘specia-
lists’ had higher caseloads than non-specialists. Half (four) of the
‘specialists’ had a caseload greater than 12 cases during 1996/7
compared with only 3% of non-specialists. Indeed only one ‘specia-
list’ performed less than six cases compared with 65% of non-
specialists. Hospital volume had an inconsistent association with
staging quality. Higher volume hospitals were more likely to docu-
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examination.
Survival data were obtained to 31st March 2000. The follow up
for patients ranged from 2.25 to 4.25 years. This follow up time is
sufﬁcient to demonstrate that there are important differences in
survival. At the date of censoring there had been 119 (17%) deaths
in those patients who had had surgical treatment.
Table 3 is a univariate survival analysis showing the association
of a number of variables with survival. These variables relate to the
patient, their tumour, and the operating surgeon and other factors
relating to processes of care. Six factors were found to be statisti-
cally signiﬁcant: FIGO stage (P50.0001) and tumour grade
(P50.0001), FIGO stage category (P50.0001), hospital caseload
category (P=0.0013), documentation of the FIGO stage (P=0.02)
and the patient age category (P=0.035).
The strength of association of the various factors was modelled
in a Cox’s proportional hazards model. The results are shown in
Table 4. The factors that were independently signiﬁcant, after
adjustment for the others, are the retrospectively assigned FIGO
stage category (P50.0001), whether adjuvant radiotherapy was
used (P=0002) and whether the patient’s FIGO stage was docu-
mented (P=0.0022).
‘Attendance at a multidisciplinary clinic’ was a statistically
signiﬁcant prognostic factor with a hazard ratio of 0.63 (95% CI:
0.42–0.94) when the model was run without ‘FIGO stage docu-
mented’ and ‘adjuvant radiotherapy used’.
More detailed analysis was performed to determine whether
there were speciﬁc FIGO stages where staging and the use of adju-
vant radiotherapy were associated with differences in survival.
These associations were statistically signiﬁcant in stages 1CG3
through to stage 3 only. Figure 1 shows the Kaplan–Meier survival
curves for this subgroup. The two curves are signiﬁcantly different,
(log rank statistic: P=0.004). Similar analysis on this subgroup was
performed looking at the effect of adjuvant radiotherapy on survi-
val. The Kaplan–Meier survival curves are shown in Figure 2. The
survival curves are signiﬁcantly different (log rank statistic:
P=0.0007). We performed a Cross-tabulation analysis to examine
the stage distribution between those patients where stage was or
was not documented in the notes. The stage distribution between
the two groups was not statistically different, w
2: P=0.21. Similarly
the stage distribution between those patients receiving radiotherapy
and not receiving radiotherapy was examined and no evidence of
any difference was found, w
2: P=0.51. Thus it is likely that these
are genuine differences in survival, representing the association
between staging being documented and of adjuvant radiotherapy
being used.
Table 5 shows the proportion of patients being referred to, or
discussed with, a clinical oncologist and the proportion of patients
in each FIGO stage category who received adjuvant radiotherapy.
DISCUSSION
One of the strengths of this study is that the data relate to a well-
deﬁned national population with a robust mechanism for case
identiﬁcation and record retrieval. We also believe that the data
quality is high. Cases were identiﬁed independently from two
sources, SMR-1 and SMR-6, and over 95% of identiﬁed records
were located and abstracted. The actual histo-pathology report
was available in 96% of cases. The pathology report was missing
from the case record in the remaining 4%, however the diagnosis
was conﬁrmed in correspondence between consultant and general
practitioner.
A new ﬁnding was the association between the MRCOG pass date
and the quality of staging. Taken together the ‘specialist effect’ and
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Table 1 Univariate analysis of factors associated with staging quality
FIGO stage documented Peritoneal cytology done
n
a Yes % w
2 Yes % w
2
MRCOG pass date
51989 481 167 (34.7) P=0.067 192 (39.9) P50.0001
4=1989 175 74 (42.5) 108 (61.7)
Surgeon category
Not ‘specialist’ 616 211 (34.3) P=0.0016 246 (39.9) P50.0001
Gynaecology cancer specialist 87 45 (51.7) 66 (75.9)
Surgeon caseload
b
Low (1–5 cases) 284 95 (33.6) P=0.35 110 (38.7) P50.0001
Intermediate (6–11 cases) 272 107 (39.3) 120 (44.1)
High (4=12 cases) 111 42 (37.8) 72 (64.9)
Hospital volume
b
Low (520 cases) 132 25 (18.9) P50.0001 64 (48.5) P=0.002
Intermediate (20–39 cases) 361 124 (34.4) 138 (38.2)
High (440 cases) 199 103 (51.8) 105 (52.8)
aCounts of missing values not displayed for clarity;
bNumber of cases of endometrial cancer operated on during
1996 and 1997.
Table 2 Multiple logistic regression analysis of factors associated with
differences in staging quality
FIGO documented Cytology sent
Odds ratio Odds ratio
(95% CI) P value (95% CI) P value
Surgeon category
Not ‘specialist’ 1 P=0.0012 1 P50.0001
Gynaecology cancer 2.6 (1.5–4.5) 4.8 (2.6–8.9)
‘specialist’
MRCOG pass date
51989 1 P=0.001 1 P50.0001
4=1989 1.9 (1.3–2.8) 3.2 (2.2–4.7)
Surgeon caseload
Low (1–5 cases) 1 P=0.03 1 P=0.16
Intermediate (6–11 cases) 1.2 (0.8–1.8) 1.4 (1.0–2.1)
High (4=12 cases) 0.6 (0.3–1.0) 1.3 (0.7–2.3)
Hospital volume
Low (520 cases) 1 P=0.0001 1 P=0.002
Intermediate (20–39 cases) 2.0 (1.2–3.4) 0.5 (0.3–0.8)
High (440 cases) 4.5 (2.6–7.9) 0.9 (0.6–1.5)
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(12), 1837–1842the ‘MRCOG date’ point towards knowledge being the common
factor that results in improved staging quality. Younger gynaecolo-
gists may have more up to date knowledge of the current staging
system and may be more aware of the beneﬁts of staging. No inde-
pendent association was found between surgeon caseload and
staging quality despite the fact that 80% of cases were performed
by gynaecologists operating on less than six cases a year. The asso-
ciation between hospital volume and staging quality is inconsistent.
These ﬁndings support data from other studies where specialist
surgeons were observed to stage more adequately (Kingsmore et
al, 1998). Of note is the fact that basic staging procedures are not
technically difﬁcult. Sending intra-peritoneal washings for cytology
requires no particular skill, only to remember that they should be
taken and a belief that it is worthwhile. Likewise, recording the
FIGO stage in the notes requires recognition of its importance,
knowledge of the staging system and remembering to do it. ‘Specia-
lists’ were more likely to document stage. These ﬁndings support the
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Table 3 Univariate analysis of survival: tumour, patient, surgeon and
process factors
No. of 2-year survival Log rank statistic
Factor deaths n (%) (P value)
FIGO stage
Cis 0 6 100 50.0001
1 54 511 93.5
2 8 59 89.8
3 39 68 57.4
4 8 13 15.4
Don’t know
a 10 43 81.4
Histological grade
1 10 217 98.6 50.0001
2 43 288 91.0
3 53 136 66.2
FIGO stage category
Low (Cis, 1AG1, 1BG1) 7 182 98.4 50.0001
Intermediate (1AG2/3, 34 289 93.1
1BG2/3, 1CG1/2)
High (1CG3, stages 2, 3 & 4) 68 182 69.8
Uncategorisable 10 50 82.0
Age
560 15 135 90.4 0.035
4=60 103 545 86.4
FIGO stage deﬁned
No 87 446 85.4 0.020
Yes 32 256 91.4
Hospital caseload category
Low (520 cases) 33 132 85.6 0.0013
Intermediate (21–39 cases) 51 361 89.5
High (440 cases) 30 199 86.9
Adjuvant radiotherapy given
No 67 428 87.6 0.30
Yes 52 275 87.6
Socio-economic deprivation
Least deprived 18 125 92.0 0.60
Intermediate deprivation 87 490 86.7
Most deprived 14 88 86.4
‘Specialist’
No 103 616 88.6 0.69
Yes 16 87 80.5
Multidisciplinary clinic
No 63 378 88.6 0.80
Yes 55 315 86.7
MRCOG date
51989 77 481 87.1 0.92
4=1989 29 175 90.3
Surgeon workload category
Low (56 cases) 48 284 89.1 0.97
Intermediate (6–11 cases) 43 272 87.5
High (412 cases) 18 111 84.7
a‘Don’t knows’ for other prognostic factors not displayed for clarity.
Table 4 Multivariate survival analysis: Cox proportional hazards model
Variable Hazard ratio 95% CI P value
FIGO stage category
Low risk 1 – –
Intermediate risk 3.6 1.5–8.8 0.0046
High risk 23.6 9.8–56.7 0.0000
Not categorisable 5.3 1.8–15.4 0.0020
Adjuvant radiotherapy used
Yes 1 – –
No 2.2 1.5–3.5 0.0002
FIGO stage documented
Yes 1 – –
No 2.0 1.3–3.1 0.0022
1.0
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C
u
m
u
l
a
t
i
v
e
 
s
u
r
v
i
v
a
l
 
(
%
)
Time (days)
0           365         730        1095      1460       1825
Log rank statistic: P=0.004
Yes
No
Yes
No
FIGO stage in notes?
Figure 1 Kaplan–Meier survival curve: association of documentation of
FIGO stage with survival: FIGO stage 1CG3, stage 2 and stage 3 disease
only. FIGO stage documented in 73 patients vs not documented in 92
patients. Vertical bar represents censored cases.
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Adjuv’t radiotherapy
Figure 2 Kaplan–Meier survival curve: association of use of adjuvant
radiotherapy with survival in patients with FIGO stage 1CG3, stage 2 and
stage 3 disease only. One hundred and twenty-four patients received
adjuvant radiotherapy vs 42 patients not receiving radiotherapy. Vertical
bar represents censored cases.
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British Journal of Cancer (2002) 86(12), 1837–1842 ã 2002 Cancer Research UKidea that part of the ‘specialist effect’ is a greater understanding of
the reasons for the surgery performed.
The survival analysis demonstrated that the process of staging
remained a statistically signiﬁcant prognostic factor even after
adjusting for other known factors including the use of adjuvant
radiotherapy. This conﬁrms and emphasises its importance. It is
not proposed that this process itself confers a direct surgical bene-
ﬁt. This point is important since advanced staging procedures such
as pelvic lymphadenectomy and para-aortic lymphadenectomy,
more commonly performed in other countries such as the United
States, have been argued as surgically therapeutic in their own right
(Orr, 1998). These more aggressive staging procedures were
uncommonly performed in this Scottish cohort (4% patients had
pelvic lymphadenectomy and only 0.57% had para-aortic lympha-
denectomy). It is more likely that staging is a proxy marker of
overall quality in the patient management process.
At the time of deﬁning the stage, all relevant details pertaining
to the disease are brought together. This collation and standardisa-
tion probably facilitates decision-making. This is important where
a patient requires referral to another clinician for further manage-
ment. This situation is common in the management of many
cancers. The association of the multidisciplinary clinic to survival
has been previously shown for ovarian cancer (Junor et al, 1994).
Attendance at a multidisciplinary clinic is statistically signiﬁcant
for patients in this study only when the variables, ‘staging docu-
mented’ and ‘use of adjuvant radiotherapy’ are removed from
the multivariate analysis. This suggests that in this cohort at least,
part of the ‘multidisciplinary effect’ may be related to the adequacy
of staging and the concomitant use of adjuvant radiotherapy in
‘high risk’ patients. This means that the multidisciplinary clinic
might contribute to patient survival by providing a mechanism
to ensure that those patients who need adjuvant treatments actually
receive them. This point is emphasised by the data in Table 5.
The use of adjuvant radiotherapy was a signiﬁcant prognostic
factor too. The effect of adjuvant radiotherapy was particularly
important in more advanced disease (Figure 2). Adjuvant radio-
therapy is known to reduce local recurrence, however its effect
on actual survival outcome is less certain (Lawton, 1997). These
results suggest that adjuvant radiotherapy is associated with
improved survival in patients with advanced disease.
‘Specialist’ status and the year of the surgeons’ MRCOG exam-
ination had no independent association with survival in this
multivariate model. The lack of an independent ‘specialist effect’
suggests that it is more important what is done than who does
it. However, ‘specialists’ operated on only 87 cases (12%) and
the study may have been underpowered to determine the true
strength of this relationship. It is acknowledged that there may
be some disagreement with our deﬁnition of a ‘specialist’, however
this was a pragmatic deﬁnition which aimed to deﬁne those clini-
cians who both had a ‘declared’ interest in gynaecological cancer
and who had the surgical capability to manage endometrial cancer.
Further analysis was performed to see whether there were speci-
ﬁc groups of patients who might have beneﬁted from better
quality staging or adjuvant radiotherapy. The prognostic beneﬁt
of staging and of radiotherapy was limited to FIGO stages
1CG3, stage 2 and stage 3. A proportion of those patients
(25.3%) did not receive adjuvant radiotherapy. This probably
represents genuine under-treatment of disease in this group.
Moreover, many of these patients had no stage documented,
despite the fact that the information to do so was contained with-
in the patient’s case notes.
CONCLUSIONS
This study shows that the overall quality of staging was poorly
performed and that adjuvant radiotherapy was inconsistently used
particularly in more advanced tumours. Staging, as a process, is a
prognostic factor particularly in patients with more advanced
cancer. It is likely that the main beneﬁt of staging is to provide
key information required for subsequent clinical management deci-
sions, particularly within the multidisciplinary context. One of the
most important decisions is whether the patient should receive any
further treatment. These results support a greater emphasis towards
improving the overall quality of surgical staging. In particular there
needs to be an improvement in the understanding of the purpose
of surgery, not just to remove the cancer, but also to provide the
information required for subsequent management decisions. This is
especially important in Scotland where endometrial cancer
continues to be managed by general gynaecologists rather than
specialist gynaecological oncologists. These results support the stra-
tegies being developed for the management of endometrial cancer
in England.
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